The immunobiological effects of interleukin-2 in vivo

Interleukin-2 (IL-2) therapy is active mainly in melanoma and renal-cell carcinoma, and 20% of the patients suffering from these cancers respond to IL-2 therapy, mostly with a partial remission. A major drawback of IL-2 therapy is its toxicity. The most severe manifestation of toxicity is the capillary-leak syndrome. Other manifestations are fever… CONTINUE READING